MDD5D5MDhsCpLFPsCLhpheD5hp5UTMDTPUFKMLDp5Kh5MDp5LPFhLsCLhpT5UMPTKFUhDpDabcoPFMK5DsphL5LsCLhpTPKUFhDpT5UMDiiiiLumnescence countsLumnescence countsLumnescence countsLumnescence countspLenti-KpLenti-C#3sh-K#1sh-Kontrolsh-CR)DR)5eMLntro + nti-KsCeR)DR)D (3’ + nti-KD (3’nti-G + esolDolntronti-G + eD (3’ + nti-KeD (3’nti-G + esLolntro + nti-Ksolntronti-G + eMDspDKMD5MR)DR)ML5entro + nti-KCeD (3’ + nti-KD (3’ + nti-GesolDholntrnti-G + eDMsp800150100015025002004000200図1 KDM5Dノックダウンによるがん細胞形質の変化a: LNCaP細胞へのshRNAs、LNCaP-104R2細胞へのKDM5Dのoverexpression、b: LNCaP sh-RNAsを使用したsoft agar colony formation assay、c: LNCaP細胞を用いたKDM5D-3'UTRへのshRNA、KDM5D overexpressionによるレスキュー実験系の作製。それらの細胞株を用いたin vivoでの去勢抵抗性増殖の形質獲得の確認。37Luminescence measurement every 2 weeks (n=5: each group) Surgical castration 2 weekOrthotopic inoculation to the prostate Tumor formation 0 week2 week4 week6 week8 weekKDM5DH3KDM5DH3LNCaP sh-ControlLNCaP sh-KDM5D#1LNCaP sh-KDM5D#3200um
元のページ ../index.html#51